Rocket Pharmaceuticals, Inc. RCKT
2.64 USD +0.13 (+5.18%)
Nov 4, 2026, 9:33 AM EST
2.57 Day range 2.62
2.17 52-week range 5.45
- YTD
- -24.79%
- 1 year
- -25.84%
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 40.93 +1450.3% upside
Now 2.64
- Target (low)
- 29.00
- Target (mean)
- 40.93
- Target (high)
- 55.00
Ratings (0m) 17 16 buy · 1 hold · 0 sell
- Strong buy4
- Buy12
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 17
- 1 month ago 17
- 2 months ago 18
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.6125 | -0.82 – -0.50004 | -0.66 | +7.2% | 888.89K | 0.0% | 12 |
| Next quarter | -0.61976 | -0.87 – -0.49717 | -0.74 | +16.3% | 1.11M | 0.0% | 12 |
| Current year | -2.23 | -3.37 – -0.30 | -2.73 | +18.4% | 42.90M | 0.0% | 16 |
| Next year | -1.62 | -2.51 – -0.04 | -2.23 | +27.3% | 96.32M | +124.5% | 16 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 3, 2025 | Scotiabank | Maintained | Sector Outperform | Sector Outperform |
| Mar 3, 2025 | Goldman Sachs | Maintained | Neutral | Neutral |
| Mar 3, 2025 | Canaccord Genuity | Maintained | Buy | Buy |
| Feb 28, 2025 | Chardan Capital | Maintained | Buy | Buy |
| Feb 28, 2025 | Needham | Maintained | Buy | Buy |
| Dec 18, 2024 | Jefferies | Initiated | — | Buy |
| Nov 19, 2024 | Canaccord Genuity | Maintained | Buy | Buy |
| Nov 19, 2024 | Leerink Partners | Maintained | Outperform | Outperform |
| Nov 19, 2024 | Cantor Fitzgerald | Reiterated | Overweight | Overweight |
| Nov 19, 2024 | Needham | Reiterated | Buy | Buy |
| Nov 18, 2024 | Chardan Capital | Maintained | Buy | Buy |
| Nov 11, 2024 | Chardan Capital | Maintained | Buy | Buy |
| Nov 8, 2024 | Needham | Reiterated | Buy | Buy |
| Oct 16, 2024 | Scotiabank | Initiated | — | Sector Outperform |
| Sep 30, 2024 | Canaccord Genuity | Maintained | Buy | Buy |
| Sep 17, 2024 | Needham | Reiterated | Buy | Buy |
| Aug 6, 2024 | JP Morgan | Maintained | Overweight | Overweight |
| Aug 6, 2024 | Cantor Fitzgerald | Reiterated | Overweight | Overweight |
| Aug 6, 2024 | Chardan Capital | Maintained | Buy | Buy |
| Aug 6, 2024 | Needham | Reiterated | Buy | Buy |
| Jul 3, 2024 | Canaccord Genuity | Maintained | Buy | Buy |
| Jun 28, 2024 | Chardan Capital | Maintained | Buy | Buy |
| Jun 28, 2024 | Needham | Maintained | Buy | Buy |
| May 7, 2024 | Needham | Reiterated | Buy | Buy |
| Apr 10, 2024 | Needham | Reiterated | Buy | Buy |
| Apr 2, 2024 | Goldman Sachs | Initiated | — | Neutral |
| Mar 1, 2024 | UBS | Maintained | Buy | Buy |
| Feb 27, 2024 | JP Morgan | Maintained | Overweight | Overweight |
| Feb 27, 2024 | Cantor Fitzgerald | Maintained | Overweight | Overweight |
| Feb 13, 2024 | Needham | Reiterated | Buy | Buy |